Makale detayı · 2024
New Benzimidazole-Triazole Derivatives as Topoisomerase I Inhibitors: Design, Synthesis, Anticancer Screening, and Molecular Modeling Studies
- Yıl
- 2024
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı ACS Omega
- Katalog eşleşmesi (ISSN) ACS Omega
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
High Resolution Image Download MS PowerPoint Slide In this study, we designed, synthesized, and evaluated a series of 1,2,4-triazole benzimidazoles for their cytotoxic effects against the A549, C6, and NIH3T3 cell lines. Additionally, these compounds were assessed for their inhibitory activity against DNA topoisomerase I, aiming to develop novel anticancer agents. The synthesized final compounds 4a – h were characterized using 1 H NMR, 13 C NMR, and HRMS. Among them, compounds 4b and 4h emerged as the most potent agents against the A549 cell line, exhibiting an IC 50 value of 7.34 ± 0.21 μM and 4.56 ± 0.18 μM, respectively. These results were compared to standard drugs, doxorubicin (IC 50 = 12.420 ± 0.5 μM) and Hoechst 33342 (IC 50 = 0.422 ± 0.02 μM). Notably, all tested compounds displayed higher cytotoxicity toward A549 cells than C6 cells. Compounds 4b and 4h demonstrated significant inhibitory activity against topoisomerase I, highlighting their potential as lead compounds in anticancer therapy. Subsequent in silico molecular docking studies were conducted to elucidate the potential binding interactions of compounds 4b and 4h with the target enzyme topoisomerase I. Molecular dynamics studies also assessed and validated the binding affinity and stability. These studies confirmed the promising binding affinity of these compounds, reinforcing their status as lead candidates. According to DFT, compound 4b having the lower energy gap value (Δ E = 3.598 eV) is more chemically reactive than the others, which is consistent with significant inhibitory activity against topoisomerase I. Furthermore, in silico ADME profiles for compounds 4b and 4h were evaluated using SwissADME, providing insights into their pharmacokinetic properties.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
19 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 20 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Novel triazole-urea hybrids as promising EGFR inhibitors: Synthesis, molecular modeling and antiproliferative activity studies against breast cancer 2025
- Novel triazole-urea hybrids as promising EGFR inhibitors: Synthesis, molecular modeling and antiproliferative activity studies against breast cancer 2025
- Design, synthesis, and antiproliferative activity evaluation of novel cyclic secondary amine containing dithiocarbamate derivatives as potent EGFR inhibitors 2025
- Synthesis of new piperazine‐oxadiazole derivatives and investigation of their anticancer activities 2025
- Novel triazole-urea hybrids as promising EGFR inhibitors: Synthesis, molecular modeling and antiproliferative activity studies against breast cancer 2025
- Novel triazole-urea hybrids as promising EGFR inhibitors: Synthesis, molecular modeling and antiproliferative activity studies against breast cancer 2025
- Design, synthesis, and antiproliferative activity evaluation of novel cyclic secondary amine containing dithiocarbamate derivatives as potent EGFR inhibitors 2025
- Synthesis of new piperazine‐oxadiazole derivatives and investigation of their anticancer activities 2025
- Synthesis of new piperazine‐oxadiazole derivatives and investigation of their anticancer activities 2025
- Synthesis of new piperazine‐oxadiazole derivatives and investigation of their anticancer activities 2025